{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:07:19Z","timestamp":1753895239455,"version":"3.41.2"},"reference-count":0,"publisher":"Wiley","issue":"4S3","license":[{"start":{"date-parts":[[2014,11,2]],"date-time":"2014-11-02T00:00:00Z","timestamp":1414886400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of the International AIDS Society"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Switching therapy studies are usually designed as second\u2010line antiretroviral treatment (ART) in patients without previous virologic failures. Combined ART (cART) with DRV\/r and ETR has a good pharmacokinetic profile, high genetic barrier and has been proved as rescue therapy. The aim of our study was to analyze efficacy and safety of therapy with DRV\/r plus ETR in treatment experienced HIV\u2010patients with previous therapeutic failures that need to switch ART. We present results at first 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Multicentre retrospective observational study. Inclusion criteria: adult HIV\u2010patients on ART with HIV\u2010VL &lt;1000 cop\/mL who started their ART with DRV\/r (600\/100 bid or 800\/100 qd)+ETR by adverse events, non\u2010adherence, tolerability or prevention of future complications. Patients with acute AIDS events, HBV, pregnancy, drug addiction or previous selected mutations to DRV or ETR were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010nine patients were included, mean age: 47 years (r: 22\u201379); 70% men, 40.4% previous AIDS event and 39.3% HCV. Ninety\u2010one patients had received \u22653 cART regimens and 45\u22655, 75 patients had HIV\u2010VL &lt;50 cop\/mL and 24 low\u2010level viremia (LLV): 297.5\u00b1261.4 cop\/mL, CD4+ 568\u00b1279 cells\/\u00b5L. ART before switching: NRTI+PI\/r (33%), NNRTI (17%), PI\/r+NNRTI (23%), PI\/r+INI (13%), other (14%). Main reason to switching was: toxicity\/intolerance 50 patients (renal 32%, gastrointestinal: 14%, hyperlipidaemia 10%; osteopenia\/osteoporosis: 6%); improving adherence 26 patients; prevention of complications 19 patients. Nine subjects withdrew ART during follow\u2010up because: intolerance or new toxicity three; non\u2010adherence two; simplification to DRV\/r monotherapy two; persistence of previous toxicity one; virologic failure one. At week 24, among patients who continued with DRV\/r+ETR (n=90): 81 (89%) had VL&lt;50 cop\/mL, in those with with HIV\u2010VL&lt;50 at baseline (67\/90), 94% persisted with &lt;50 cop., and in those with LLV (24\/90), 61% (n=14) achieved a VL&lt;50 cop. We didn't observe any significant difference in lab parameters between baseline and week 24. Estimated glomerular filtrate rate increased from 83.4\u00b124.7 to 88.5\u00b156.8 mL\/min, p=NS. Regarding reason to switching, it improved in 42 cases, no changes: 20 cases; worsened: 4 cases, and non\u2010applicable or unknown: 24 cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Switching to dual therapy with DRV\/r+ETR is an effective strategy in selected heavily experienced ART patients, even in those with LLV (&lt;1000 cop\/mL). This cART is safe and well tolerated, can reduce number of pills and improve adherence.<\/jats:p><\/jats:sec>","DOI":"10.7448\/ias.17.4.19803","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T08:30:34Z","timestamp":1415003434000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual therapy with darunavir\/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV\u2010patients. The BITER Study"],"prefix":"10.1002","volume":"17","author":[{"given":"Joaqu\u00edn","family":"Portilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piedad","family":"Arazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"Crusells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"P\u00e9rez\u2010Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofre","family":"Mart\u00ednez\u2010Madrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Reus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Galera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Jover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepcion","family":"Amador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Saiz\u2010de\u2010la\u2010Hoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,2]]},"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.7448%2FIAS.17.4.19803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.7448\/IAS.17.4.19803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:13:50Z","timestamp":1695575630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.7448\/IAS.17.4.19803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":0,"journal-issue":{"issue":"4S3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.7448\/IAS.17.4.19803"],"URL":"https:\/\/doi.org\/10.7448\/ias.17.4.19803","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"type":"print","value":"1758-2652"},{"type":"electronic","value":"1758-2652"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"19803"}}